Canada markets closed

Science 37 Holdings, Inc. (SNCE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.71-0.01 (-0.17%)
At close: 03:59PM EST
5.62 -0.09 (-1.58%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close5.72
Bid5.72 x 2900
Ask5.73 x 1300
Day's Range5.70 - 5.74
52 Week Range3.73 - 12.96
Avg. Volume50,811
Market Cap34.421M
Beta (5Y Monthly)0.54
PE Ratio (TTM)N/A
EPS (TTM)-21.40
Earnings DateMar 04, 2024 - Mar 08, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.83
  • PR Newswire

    eMed commences tender offer for Science 37

    eMed, LLC ("eMed") today announced that its wholly-owned subsidiary, Marlin Merger Sub Corporation, a Delaware corporation ("Purchaser"), has commenced a cash tender offer to purchase all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) ("Science 37") for a price of $5.75 per share (the "Offer"). The Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated February 12, 2024 and the r

  • GlobeNewswire

    Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment

    Science 37 stockholders to receive $5.75 per share in cashRESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today announced that it has entered into a definitive merger agreement to be acquired by eMed, LLC (“eMed”), the leader in on-demand virtual care and treatment for consumers. With the most authoritative in-home testing and treatment solution available

  • GlobeNewswire

    Science 37 Receives Top Honors in Everest PEAK Matrix®

    Science 37 emerges as the only clinical trial site to be recognized as a Leader in Decentralized Clinical TrialsRESEARCH TRIANGLE PARK, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ today announced that it has been named a Leader in the Decentralized Clinical Trials (DCT) PEAK Matrix® Assessment by the Everest Group, for the third consecutive year. The only clinical trial site to be named as a Leader in the PEAK